G.S.R-360-E-dt.-10-04-2018-New-Drug-word-Patent-and-properietry-subsituted-as-word-Drug.pdfGSR-45E-dt-24-01-2011-Vaccines-and-Recombinant-are-new-drugs-Drugs-and-Cosmetics-1st-Amendment-Rules-2011.pdfGSR-99E-dt-05-02-2021-Draft-notification-For-inclusion-of-provisions-related-to-the-registration-of-stand-alone-bio-analytical-laboratories-in-the-NDCT-Rules-2019.pdfGSR-175E-dt-09-03-2023-New-Drug-and-Clinical-Trial-Amendment-Rules-2023-additional-testing-methods-to-assess-safety-efficacy-of-iPSC-included.pdfGSR-227-E-dt-19-03-2019-New-Drugs-and-Clinical-Trials-Rules-2019.pdfGSR-605E-dt-31-08-2021-Standalone-Bioanalytica-New-Drugs-and-Clinical-Trials-Amendment-Rules-2021.pdfGSR-738E-dt-09-10-2009-Amendment-in-the-notification-number-G.S.R.-578E-23rd-July-1983-Substitutes-FDC-of-Corticosteroid-with-any-other-drug-for-internal-use.pdfGSR-767E-dt-27-10-2021-Draft-to-amend-rule-2-to-substitute-cell-or-stem-cell-derived-product-under-NDCTR-2019.pdfGSR-778E-dt-14-10-2022-New-Drugs-and-Clinical-Trials-Third-Amendment-Rules-2022.pdfGSR-No.-21E-dt-18-01-2022-Designated-Registration-Authority-in-Form-CT-3-New-Drugs-and-Clinical-Trials-2nd-Amendment-Rules-2022.pdfGSR-No.-32E-dt-21-01-2022-Draft-notification-Insertion-of-Proviso-for-deemed-approvals-in-Rule-8-under-New-Drugs-and-Clinical-Trials-Rules-2019.pdfGSR-No.-354E-05-06-2020-New-Drugs-and-trial-Rules-2020-draft.pdfGSR-No.-364E-dt-11-05-2023-Draft-New-Drugs-and-Clinical-Trials-Amendment-Rules-2022.pdfGSR-No.-524-dt-02-08-2021-DRaft-New-Drugs-and-Clinical-TrialAmendment-Rules-2021.pdfS.O.-553E-dt-09-02-2022-Stockpiling-of-new-drug-under-phase-3-of-clinical-trial-New-Drugs-and-Clinical-Trials-Rules-2019.pdf